Financial News

Eli Lilly shares gained after late-stage Foundayo data showed double-digit weight loss in adults aged 65 and older across obesity trials.

The findings could broaden the long-term opportunity for obesity and diabetes treatments.

Dell hits a 52-week high as analysts boost price targets ahead of Q1 earnings, citing "parabolic" AI infrastructure demand.

While retatrutide may have the best weight loss efficacy to date, analysts hold concerns about its tolerability profile compared with best-seller, tirzepatide.

https://investor.lilly.com/news-releases/news-release-details/foundayo-orforglipron-once-daily-pill-taken-without-food-or

While Eli Lilly reigns supreme, Idea Pharma’s annual R&D ranking reveals which other large pharmas are on the rise — and which are stumbling.

Eli Lilly said on Thursday its retatrutide cleared a late-stage trial, helping patients lose an average 29% of their weight across 80 weeks.

Eli Lilly (NYSE:LLY) has agreed to acquire Engage Biologics in a deal worth up to $202 million. Engage Biologics is developing Tethosome, a non-viral DNA delivery platform for genetic medicines. This transaction is Lilly’s seventh acquisition of 2026 and is intended to expand its genetic medicines capabilities. Eli Lilly comes into this deal with strong recent stock performance, with the share price at $1,041.65 and up 15.4% over the past 30 days and 3.5% over the past week. Over the past...

Eli Lilly and Company (NYSE: LLY) today announced the details of presentations from across its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2 in Chicago, Illinois.

Late-stage trial data strengthens Lilly's obesity drug pipeline.

Retatrutide helped patients lose up to 28.3% of body weight over 80 weeks.

Jared Holz, Mizuho, joins 'Fast Money' to talk the latest numbers from Eli Lilly's obesity shot data.

Eli Lilly and Company (NYSE:LLY), featuring a net income margin of 34.99% and upside potential of 20.64%, secures a spot on our list of the best extremely profitable stocks to buy according to Wall Street analysts. The company reported net income of $20.64 billion for the recently completed fiscal year (FY25). That earnings strength was […]

The U.S. government is stepping directly into the quantum race, committing billions in incentives — and taking equity stakes in the companies it’s backing.

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

The GLP-1 agonists weight loss drugs market offers growth potential through rising obesity rates, innovative drug approvals, and increased insurance coverage. Opportunities include expanding obesity clinics, leveraging GLP-1 therapies beyond diabetes, and addressing production cost challenges due to tariffs. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Glucagon-Like Pe

Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.

Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.

LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.

Eli Lilly’s investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.

Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.

The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome

Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.

Eli Lilly (LLY) said Thursday its investigational triple hormone receptor agonist retatrutide delive

Wall Street has rediscovered the stock-split playbook. KLA (NASDAQ: KLAC) announced a 10-for-1 forward stock split in May 2026 alongside a fiscal Q3 earnings beat and a roughly 21% dividend hike, with the stock trading in the $1,800 range. Earlier in the year, Booking Holdings (NASDAQ: BKNG) completed a 25-for-1 split announced in February 2026, taking ... Will ASML, Lilly, or TransDigm Be the Next Big Stock Split?

Eli Lilly (NYSE:LLY) shares gained around 2% in premarket trading on Thursday after the company released positive late-stage clinical trial results for its experimental obesity treatment retatrutide. The study showed that patients diagnosed with obesity lost an average of 28.

Demand for weight loss drugs may fuel growth for more than one player.